Full text is available at the source.
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Link between semaglutide use and risk of suicidal thoughts in real-world patients
AI simplified
Abstract
The study included 240,618 patients prescribed semaglutide or non-GLP1R agonist medications.
- Semaglutide is associated with a lower risk of incident suicidal ideation compared to non-GLP1R agonist anti-obesity medications (hazard ratio = 0.27).
- Recurrent suicidal ideation is also less likely in patients treated with semaglutide compared to non-GLP1R agonists (hazard ratio = 0.44).
- Findings are consistent across different sex, age, and ethnicity groups.
- Similar associations were observed in a larger cohort of 1,589,855 patients with type 2 diabetes.
- The results do not indicate higher risks of suicidal ideation with semaglutide compared to other medications.
AI simplified